Jeanette Dias D'Souza

$319,995.00asSenior Vice President, Group Chief Financial Officer

Employed by Ontario Institute For Cancer Research in 2025, according to Government of Ontario public salary records.

Salary Information

Historical salary and taxable benefits from 2016 to 2025.

YearPositionSalaryBenefitsPerformance
2025
Senior Vice President, Group Chief Financial Officer
$319,995.00
$1,477.44
2024
Senior Vice President, Group Chief Financial Officer
$319,995.00
$1,477.44
2023
Senior Vice President, Group Chief Financial Officer
$319,995.00
$1,462.86
2022
Senior Vice President, Group Chief Financial Officer
$319,995.00
$1,375.38
2.71%
2021
Senior Vice President, Group Chief Financial Officer
$328,915.13
$1,221.36
8.45%
2020
Vice President, Corporate Services and Chief Financial Officer
$303,277.24
$1,210.44
21.59%
2019
Vice President, Corporate Services and Chief Financial Officer
$249,431.00
$1,191.36
1.05%
2018
Vice President, Corporate Services and Chief Financial Officer
$246,840.35
$1,191.36
1.94%
2017
Vice-President Corporate Services and Chief Financial Officer
$242,134.30
$1,029.42
7.9%
2016
Chief Financial Officer and Vice President, Corporate Services
$224,413.72
$867.48

In 2025, Jeanette Dias D'Souza received a salary of $319,995.00 working as Senior Vice President, Group Chief Financial Officer at Ontario Institute For Cancer Research, as disclosed on the Ontario Sunshine List. Jeanette Dias D'Souza has appeared on the Ontario Sunshine List 10 times between 2016 and 2025, with reported earnings peaking at $328,915.13 in 2021. In addition to salary, $1,477.44 in taxable benefits was disclosed for 2025. Ontario Institute For Cancer Research reports under the Other Public Sector Employers sector of Ontario's public sector salary disclosure.

Top earning Senior Vice President, Group Chief Financial Officers in Ontario Institute For Cancer Research

NameSalary
Jeanette Dias D'Souza$319,995.00
NameSalary
Christine Williams
Acting President and Head, Implementation Science
$395,996.12
Lincoln Stein
Acting Scientific Director and Head, Adaptive Oncology
$383,286.80
Jared T. Simpson
Interim Scientific Director and Principal Investigator
$331,897.15
David E. Uehling
Interim Scientific Director, Therapeutic Innovation and Drug Discovery
$329,520.45
Peter Goodhand
Executive Lead
$321,484.80
Robert V. Campos
Senior Director
$256,531.19
Rebecca L. Tamarchak
Head, Strategy, Governance and Partnerships
$249,995.20
David M Sutton
Senior Director
$240,445.77
Juri Reimand
Principal Investigator
$233,643.01
Methvin Isaac
Senior Scientific Advisor
$229,139.58